Startling new research has linked the widespread off-label use of the hemophilia drug NovoSeven to a high number of blood clots and other thromboembolism events. Off-label uses are those not approved by the U.S. Food & Drug Administration (FDA), and are not intended by the manufacturers. Studies found that NovoSeven has been used almost exclusively for off-label purposes since it was first introduced.
Free NovoSeven Case Evaluation: If you or a loved one has been injured by NovoSeven, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.
What’s the problem?
April 25, 2011 - According to new research published in the Annals of Internal Medicine, the hemophilia medication NovoSeven has been associated with a high number of heart attacks, strokes, fatalities and other catastrophic events when used on patients for ‘off-label’ purposes. The studies concluded that NovoSeven has little more benefit to patients than a placebo, and that medium and high doses of the drug led to increased risks for blood clots in patients with brain hemorrhages who underwent cardiovascular surgery.
First approved by the FDA in 1999 for the treatment of hemophilia, NovoSeven has been used almost exclusively off-label to stop bleeding during various types of surgeries. In fact, NovoSeven was only used as prescribed - to stop bleeding in hemophiliacs - in a mere three percent of the cases.
While the practice of using drugs off-label is allowed by law, doctors do not have as much information about potential side effects of drugs as they would for approved uses. NovoSeven labels are required by the FDA to carry a ‘black box’ warning - the Administration’s strictest - but this has not stopped it from being used rampantly for off-label uses.
Do I have a NovoSeven Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in NovoSeven lawsuits. We are handling individual litigation nationwide and currently accepting new side effects cases in all 50 states.